Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Immunology Research
Cancer Immunology Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Cancer Immunology Essentials
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Meeting Abstracts

The collaboration for AIDS vaccine discovery: A model for accelerating research

Nina D. Russell
Nina D. Russell
Bill & Melinda Gates Foundation, Seattle, WA, USA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI:  Published January 2008
  • Article
  • Info & Metrics
  • PDF
Loading

Abstract

The Global HIV Vaccine Enterprise was conceived in 2003 to bring new focus, cooperation, and expanded resources to HIV vaccine research. Since its inception, the Enterprise has formed an alliance of independent organizations that includes many of the leading AIDS vaccine research institutions in the world. Together, this group has developed and begun to implement a shared Scientific Strategic Plan, helped mobilize significant new resources, promoted collaborative work among researchers, and sponsored dialogues on major scientific challenges.

The Enterprise concept was first proposed in a June 2003 article in Science signed by 24 leaders in HIV vaccine research. They called for a revitalized, more collaborative research effort that would increase the scale and accelerate the pace of research, establish common standards for comparing products, expand manufacturing capability, and improve the capacity of clinical trials sites. The Enterprise proposal was further developed at a meeting of leading scientists, public health experts and policy makers in August 2003. In 2004, at their annual Summit, the Group of 8 nations endorsed the Enterprise concept and pledged their support. The Enterprise is now engaged in a broad range of activities, but science is its core business. The initial stakeholders in the Enterprise began work on their Scientific Strategic Plan (SSP) in 2004, convening six expert working groups and conducting a comprehensive review of the state of HIV vaccine research. The SSP was published in PLoS Medicine in February 2005.

Enterprise partners are now aligning many of their activities and launching new projects to address the six priority areas identified in the SSP: vaccine discovery, laboratory standardization, product development and manufacturing, clinical trials capacity, regulatory capacity, and intellectual property issues. The first major contribution of the Bill & Melinda Gates Foundation to this initial phase of the Enterprise was the creation of a new initiative called the Collaboration for AIDS Vaccine Discovery (CAVD).

The CAVD was launched in July 2006 and is being developed as a highly collaborative network of 17 research consortia, comprised of almost 200 investigators in over 90 institutions in 22 different countries. Twelve of the consortia are working on different approaches to developing HIV vaccines, six of which focus on vaccine concepts designed to induce cell-mediated immunity, and the other six on vaccine concepts designed to induce protective antibody responses. These 12 Vaccine Discovery Consortia (VDC) are supported by five Central Service Facilities (CSFs), which conduct standardized immunological evaluations and data and statistical analysis for the whole network, allowing for real-time comparison of the results. The CAVD projects are not intended to focus on basic discovery research. Instead, they target a perceived strategic gap in the HIV vaccine research and development continuum, which is the translational or "maturation" phase. This phase is aimed at harnessing the vast amount of knowledge derived from basic research to produce the "proof-of-concept" experiments required to proceed with confidence to the product development phase. To ensure that the whole effort is bigger than the sum of its parts, the 16 CAVD consortia and centers are bound together by a robust communication and alliance management strategy, and by legal agreements to share materials and data among the different CAVD laboratories and, in time, with the rest of the Enterprise alliance and the scientific community at-large. Now at the end of their first year of funding, the CAVD teams have made considerable progress, and a brief description of the main project objectives will be provided in the presentation.

This abstract was published in Cancer Immunity, a Cancer Research Institute journal that ceased publication in 2013 and is now provided online in association with Cancer Immunology Research.

  • Copyright © 2008 by Nina D. Russell
PreviousNext
Back to top
Cancer Immunity Archive: 8 (Suppl 1)
January 2008
Volume 8, Issue Suppl 1
  • Table of Contents

Sign up for alerts

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Immunology Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
The collaboration for AIDS vaccine discovery: A model for accelerating research
(Your Name) has forwarded a page to you from Cancer Immunology Research
(Your Name) thought you would be interested in this article in Cancer Immunology Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The collaboration for AIDS vaccine discovery: A model for accelerating research
Nina D. Russell
Cancer Immun January 1 2008 (8) (Suppl 1) 8;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The collaboration for AIDS vaccine discovery: A model for accelerating research
Nina D. Russell
Cancer Immun January 1 2008 (8) (Suppl 1) 8;
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • Robust T-cell responses and clinical responses following long peptide vaccination against high risk HPV-16
  • Human monoclonal antibodies and analytic vaccinology
Show more Meeting Abstracts
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues
  • Cancer Immunology Essentials

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Immunology Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Immunology Research
eISSN: 2326-6074
ISSN: 2326-6066

Advertisement